Allergan's revenue beats on higher U.S. brand sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Mizuho Securities Reiterates Buy on Allergan (AGN) Following a 4Q Earnings Beat
February 23, 2016 7:04 AM ESTMizuho Securities maintained a Buy rating on Allergen (NYSE: AGN), and cut the price target to $330.00 (from $354.00), following the company's 4Q earnings report. AGN delivered a solid 4Q bottom line beat with revenues of $4.2B and EPS of $3.41 versus consensus estimates $4.2B and... More
